Accessibility StatementSkip Navigation — Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia — — Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 — DUBLIN, Sept. 11, 2025 /PRNewswire/ --Â Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards program ...

– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition  –– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) a ...

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of ...